MicroPort NeuroTech Limited (2172) AI Stock Analysis

• Market Cap: HK$8.30B
• Dividend Yield: 1.2%
• Average Volume (3M): 13.95M
• Price to Earnings (P/E): 37.5
• Beta (1Y): 0.94
• Revenue Growth: -5.18%
• EPS Growth: -9.69%
• Country: HK
• Employees: 527
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.17
• Shares Outstanding: 585,034,800
• 10 Day Avg. Volume: 8,563,118
• 30 Day Avg. Volume: 13,953,954
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$14.50
• Price Target Upside: 8.37% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 66 Neutral
• Price Target: HK$14.50 ▲(8.37% Upside)

MicroPort NeuroTech Limited's overall stock score is driven by strong financial performance, particularly in revenue and profit growth, and a solid balance sheet. However, technical indicators suggest a lack of momentum, and the valuation appears high, which could limit upside potential. Improving cash flow operations and addressing valuation concerns will be crucial for future stock performance.

MicroPort NeuroTech Limited Business Overview & Revenue Model

Company Description

MicroPort NeuroTech Limited engages in the research and development, production, and sale of neuro-interventional medical devices in the People's Republic of China and internationally. It offers NUMEN, a coil embolization system; NUMEN FR, a coil detachment system; Tubridge, a flow-diverting stent; Willis, an intracranial stent graft system; and Rebridge, an intracranial visualized stent for use in the treatment of hemorrhagic stroke. The company also provides APOLLO, an intracranial arterial stent system to treat intracranial atherosclerotic disease; and Bridge, a rapamycin target eluting vertebral artery stent system to treat cerebral atherosclerotic stenosis. In addition, it offers Neurohawk, a stent thrombectomy device; Tigertriever, an adjustable stent retriever for use in the treatment of acute ischemic stroke. The company was founded in 2004 and is headquartered in Shanghai, the People's Republic of China.

How the Company Makes Money

MicroPort NeuroTech Limited makes money through the sale of its neurovascular devices to hospitals, clinics, and other healthcare providers. The company's revenue model is primarily based on the direct sale of its medical devices, which are used in various neurovascular procedures. Key revenue streams include the sales of embolization coils, stents, and flow diverters, which are integral to treating complex neurovascular conditions. Additionally, the company may engage in strategic partnerships with healthcare institutions and distributors to expand its market reach and enhance product accessibility, thus contributing to its earnings.

MicroPort NeuroTech Limited Financial Statement Overview

Summary

MicroPort NeuroTech Limited exhibits strong revenue and profit growth, a solid balance sheet with low leverage, and efficient equity utilization. However, concerns about recent operational cash flow and cash generation capabilities slightly dampen the financial performance score.

Income Statement

MicroPort NeuroTech Limited has demonstrated robust revenue growth, with a notable increase from 2023 to 2024. The gross profit margin and net profit margin are strong, reflecting effective cost management and profitability. EBIT and EBITDA margins are also healthy, indicating operational efficiency and profitability. Overall, the income statement showcases a positive growth trajectory and solid profitability.

Balance Sheet

The company's balance sheet shows a low debt-to-equity ratio, signifying low leverage and financial stability. The return on equity is impressive, suggesting efficient use of equity to generate profits. However, the equity ratio indicates a high reliance on equity, which could limit leverage benefits. Overall, the balance sheet reflects financial strength with controlled liabilities.

Cash Flow

The cash flow statement reveals some concerns with operational cash flow being zero in the latest period, which could indicate cash generation issues. The free cash flow has fluctuated in previous years, but there is a lack of data for current growth assessment. Despite past positive free cash flow, the current lack of free cash flow data poses a risk to cash flow stability. The overall cash flow position needs improvement to ensure ongoing liquidity.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	761.76M	665.62M	547.35M	382.80M	221.92M
Gross Profit	555.93M	511.79M	393.00M	298.35M	164.78M
EBITDA	340.48M	221.60M	176.74M	108.83M	68.24M
Net Income	254.16M	145.55M	-21.77M	24.17M	45.29M
Balance Sheet
Total Assets	2.04B	1.96B	1.82B	1.34B	785.61M
Cash, Cash Equivalents and Short-Term Investments	995.06M	1.08B	1.13B	593.29M	425.49M
Total Debt	37.12M	61.36M	85.24M	109.70M	331.15M
Total Liabilities	335.70M	322.39M	331.35M	1.52B	412.73M
Stockholders Equity	1.71B	1.64B	1.47B	-174.94M	372.88M
Cash Flow
Free Cash Flow	227.79M	-48.83M	175.85M	99.43M	13.09M
Operating Cash Flow	284.41M	153.78M	223.80M	157.41M	47.23M
Investing Cash Flow	-160.55M	-233.16M	-344.52M	-186.79M	-73.04M
Financing Cash Flow	-226.25M	-33.28M	329.54M	200.75M	431.88M

MicroPort NeuroTech Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 13.38
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:2172, the sentiment is Negative. The current price of 13.38 is below the 20-day moving average (MA) of 13.60, below the 50-day MA of 13.91, and above the 200-day MA of 11.37, indicating a neutral trend. The MACD of -0.09 indicates Negative momentum. The RSI at 45.80 is Neutral, neither overbought nor oversold. The STOCH value of 57.25 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:2172.

MicroPort NeuroTech Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
2172	66 Neutral	HK$8.30B	37.49	11.79%	1.20%	-5.18%	-9.69%
1858	66 Neutral	8.85B	45.35	4.43%	0.91%	-32.05%	-54.47%
1302	59 Neutral	8.08B	105.62	6.36%	―	3.42%	-70.82%
2190	59 Neutral	8.29B	48.92	3.23%	0.43%	35.01%	483.73%
2160	51 Neutral	3.55B	645.45	-2.26%	―	-4.38%	0.00%
9996	41 Neutral	4.63B	-18.39	-11.17%	―	28.66%	9.02%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

MicroPort NeuroTech Limited Corporate Events

MicroPort NeuroScientific Grants Share Options to Employees

MicroPort NeuroScientific Corporation announced the granting of 402,300 share options to 63 employees as part of its Share Scheme. This initiative aims to incentivize employees by giving them a personal stake in the company, thereby promoting business development and success. The options have a ten-year validity and will vest over five years without additional performance targets, although they are subject to a clawback mechanism.

The most recent analyst rating on (HK:2172) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

MicroPort NeuroTech Reports Strong Overseas Growth Amidst Revenue Challenges

MicroPort NeuroTech Limited announced its unaudited interim results for the first half of 2025, reporting a revenue of approximately RMB382.9 million. The company experienced a significant 67.4% increase in overseas business revenue compared to the previous year, driven by strong sales across various regions. However, the revenue from flow-diverting stents decreased due to volume-based procurements, and cerebral atherosclerotic stenosis products were impacted by the termination of previous distribution agreements. Despite these challenges, the company achieved a net profit of RMB92.7 million and declared an interim dividend of HK$0.05 per share.

The most recent analyst rating on (HK:2172) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

MicroPort NeuroScientific Declares Interim Dividend for 2025

MicroPort NeuroScientific Corporation has announced an interim dividend of HKD 0.05 per share for the six months ending June 30, 2025. This announcement reflects the company’s commitment to returning value to its shareholders and may positively impact investor sentiment, reinforcing its stable financial performance and strategic growth in the neuro-intervention sector.

The most recent analyst rating on (HK:2172) stock is a Hold with a HK$17.00 price target. To see the full list of analyst forecasts on MicroPort NeuroTech Limited stock, see the HK:2172 Stock Forecast page.

MicroPort NeuroScientific Schedules Board Meeting for Interim Results Review

MicroPort NeuroScientific Corporation has announced that its board of directors will meet on August 27, 2025, to review and approve the interim results for the first half of the year ending June 30, 2025. The meeting will also consider the payment of an interim dividend and address other business matters, which could impact the company’s financial strategy and shareholder returns.

MicroPort NeuroScientific Announces Final Dividend with Scrip Option

MicroPort NeuroScientific Corporation has announced a final cash dividend with a scrip option for the year ended December 31, 2024. Shareholders can opt to receive HKD 0.11 per share in cash or convert their dividend to scrip shares at a price of HKD 11.3148 per share. The dividend will be paid on August 22, 2025, with the first date of dealing in scrip shares set for August 25, 2025. This announcement updates previous information regarding the scrip option, providing shareholders with flexibility in their dividend receipt.

MicroPort NeuroScientific Announces AGM Results and Strategic Appointments

MicroPort NeuroScientific Corporation announced the results of its Annual General Meeting held on June 27, 2025, where all proposed ordinary resolutions were passed. Key decisions included the approval of a final dividend, re-election and appointment of independent non-executive directors, and the re-appointment of auditors. These resolutions reflect the company’s strategic focus on governance and shareholder value, potentially strengthening its market position and stakeholder confidence.

MicroPort NeuroScientific Enhances Governance with New Nomination Committee

MicroPort NeuroScientific Corporation, a company incorporated in the Cayman Islands, has established a Nomination Committee as part of its corporate governance structure. The committee will be composed of a majority of independent non-executive directors and at least one member of a different gender, with the aim of ensuring diverse and balanced representation. The announcement outlines the operational framework and procedures for the Nomination Committee, including meeting protocols and the roles of its members. This initiative reflects the company’s commitment to enhancing its governance practices, potentially impacting its industry positioning by promoting transparency and inclusivity.

MicroPort NeuroScientific Announces Board Composition and Roles

MicroPort NeuroScientific Corporation has announced the composition of its board of directors and the roles within its three board committees. This announcement provides clarity on the leadership structure, which is crucial for stakeholders to understand the company’s governance and strategic direction.

MicroPort NeuroTech Enters Three-Year Distribution Agreement

MicroPort NeuroTech Limited has entered into a Master Distribution Agreement with MicroPort for a three-year term starting June 27, 2025. This agreement allows MicroPort to commercialize and distribute MicroPort NeuroTech’s neurointerventional medical devices in specified international markets. The agreement is considered a continuing connected transaction due to MicroPort’s significant shareholding in the company. The transaction is subject to certain reporting and review requirements under the Hong Kong Stock Exchange Listing Rules but is exempt from the need for independent shareholder approval. The pricing for the devices will be determined through arm’s length negotiations, ensuring competitiveness with similar products in the market.